" class="no-js "lang="en-US"> CellOrigin Biotech - Medtech Alert
Friday, June 20, 2025
CellOrigin Biotech | Pharmtech Focus

CellOrigin Biotech

About CellOrigin Biotech

CellOrigin Biotech

CellOrigin Biotech (Hangzhou) Co., Ltd. is dedicated to the development of genetically engineered pluripotent stem cell- (iPSC) derived immune cell therapies (such as macrophages, NK cells), with its own proprietary intellectual property. The founders are experienced leaders from Zhejiang University, Harvard University and top pharmaceutical and biotech companies around the world. They apply cutting-edge technologies in editing and differentiating iPSCs to immune cells in order to deliver novel allogeneic off-the-shelf cell therapies for the treatment of cancer patients around the world.

Related Story

CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy

September 26 2022

CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with […]